What does Kincell Bio do?
Kincell Bio is a contract development and manufacturing organization (CDMO) that streamlines CMC development by leveraging expertise in analytical processing and GMP manufacturing for clinical to commercial stages.
How much did they raise?
The company raised $22M in a funding round led by NewSpring Capital with participation from Kineticos Life Sciences.
What are their plans for the money?
The funds will be used to expand cGMP capabilities, enhance process development services, and support the creation of advanced solutions for emerging cell therapy companies, which could accelerate clinical trials and product launches.
What have they achieved so far?
Kincell Bio has demonstrated strong capabilities in supporting immune cell therapy programs, evidenced by its robust platform that facilitates rapid timelines from early clinical trials to pivotal studies and product launches, and the strategic appointment of Pete Buzy to its board further underscores its industry leadership.
